Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

WITHDRAWN: Rizatriptan for acute migraine.

A D Oldman1, L A Smith, H J McQuay

  • 1Churchill Hospital, c/o Pain Research Unit, Old Road, Headington, Oxford, UK, OX3 7LJ.

The Cochrane Database of Systematic Reviews
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using Advanced Cell Culture Techniques to Differentiate Pluripotent Stem Cells and Recreate Tissue Structures Representative of Teratoma Xenografts.

Frontiers in cell and developmental biology·2021
Same author

Applications of novel bioreactor technology to enhance the viability and function of cultured cells and tissues.

Interface focus·2020
Same author

Ubiquitous parasites drive a 33% increase in methane yield from livestock.

International journal for parasitology·2018
Same author

To fill or not to fill: a qualitative cross-country study on dentists' decisions in managing non-cavitated proximal caries lesions.

Implementation science : IS·2018
Same author

Correction to: Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy.

BMC anesthesiology·2017
Same author

Can BAPEN do more to advance nutrition training amongst trainee doctors? Results of the first UK BAPEN medical trainee group survey.

Clinical nutrition ESPEN·2017
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Rizatriptan effectively treats acute migraine attacks. Both 5 mg and 10 mg doses showed significant benefits over placebo, with higher doses offering increased efficacy for migraine relief.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Acute migraine treatment involves various drug options, including triptans.
  • Evidence-based data is crucial for assessing the benefit-harm balance of acute migraine therapies.

Purpose of the Study:

  • To evaluate the efficacy of rizatriptan (Maxalt) for acute migraine relief.
  • To quantify headache and pain-free responses at various time points and sustained relief over 24 hours.
  • To determine the number-needed-to-treat (NNT) for rizatriptan.

Main Methods:

  • Systematic review of randomized, placebo-controlled trials of rizatriptan for acute migraine.
  • Inclusion criteria specified double-blind design, adult population, moderate to severe pain, and specific efficacy outcome data.
  • Data extraction included dichotomous or percentage data to calculate relative benefit and NNT.

Related Experiment Videos

Main Results:

  • Seven trials involving 2626 patients treated with rizatriptan and 902 with placebo were analyzed.
  • Rizatriptan (5 mg and 10 mg) demonstrated significant benefits over placebo for all main efficacy outcomes up to 24 hours.
  • A dose-response relationship was observed, indicating increased efficacy with higher doses.

Conclusions:

  • Rizatriptan, at both 5 mg and 10 mg doses, is an effective treatment for acute migraine.
  • Efficacy increases in a dose-dependent manner.